@article{356c5e1d78094752a02e9308a381e7c7,
title = "RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer",
abstract = "Wnt/β-catenin signaling is a primary pathway for stem cell maintenance during tissue renewal and a frequent target for mutations in cancer. Impaired Wnt receptor endocytosis due to loss of the ubiquitin ligase RNF43 gives rise to Wnt-hypersensitive tumors that are susceptible to anti-Wnt-based therapy. Contrary to this paradigm, we identify a class of RNF43 truncating cancer mutations that induce β-catenin-mediated transcription, despite exhibiting retained Wnt receptor downregulation. These mutations interfere with a ubiquitin-independent suppressor role of the RNF43 cytosolic tail that involves Casein kinase 1 (CK1) binding and phosphorylation. Mechanistically, truncated RNF43 variants trap CK1 at the plasma membrane, thereby preventing β-catenin turnover and propelling ligand-independent target gene transcription. Gene editing of human colon stem cells shows that RNF43 truncations cooperate with p53 loss to drive a niche-independent program for self-renewal and proliferation. Moreover, these RNF43 variants confer decreased sensitivity to anti-Wnt-based therapy. Our data demonstrate the relevance of studying patient-derived mutations for understanding disease mechanisms and improved applications of precision medicine.",
keywords = "cancer mutations, human colon organoids, PORCN inhibitors, RNF43, Wnt signaling",
author = "Maureen Spit and Nicola Fenderico and Ingrid Jordens and Tomasz Radaszkiewicz and Lindeboom, {Rik G.H.} and Bugter, {Jeroen M.} and Alba Cristobal and Lars Ootes and {van Osch}, Max and Eline Janssen and Boonekamp, {Kim E.} and Katerina Hanakova and David Potesil and Zbynek Zdrahal and Boj, {Sylvia F.} and Medema, {Jan Paul} and Vitezslav Bryja and Koo, {Bon Kyoung} and Michiel Vermeulen and Maurice, {Madelon M.}",
note = "Funding Information: We thank members of the laboratory of M.M.M. for discussions and suggestions. We thank Cara Jamieson for providing ‐KO cells and Manja Omerzu and Lars Kemp for ‐KO cells; Jarno Drost (Princess M{\'a}xima Centre for Paediatric Oncology, Utrecht, Netherlands) for gRNA. This work is part of the Oncode Institute, which is partly financed by the Dutch Cancer Society. This work was supported by European Research Council Starting Grant 242958, the Netherlands Organization for Scientific Research NWO VICI Grant 91815604, ECHO Grant 711.013.012, and TOP Grant 91218050 (to M.M.M.), European Union Grant FP7 Marie Curie ITN 608180 “WntsApp” (to M.M.M.). V.B., T.R., and Z.Z. were supported by the Czech Science Foundation (project no. GX19‐28347X). Projects CEITEC 2020 (LQ1601) and CIISB research infrastructure (LM2018127) from the Ministry of Education, Youth and Sports of the Czech Republic supported D.P. and K.H. who performed the LC‐MS/MS measurements at the CEITEC Proteomics Core Facility. M.V. is supported by an ERC Consolidator Grant (771059). RNF43/ZNRF3 AXIN2 TP53 Publisher Copyright: {\textcopyright} 2020 The Authors. Published under the terms of the CC BY 4.0 license",
year = "2020",
month = sep,
day = "15",
doi = "10.15252/embj.2019103932",
language = "English",
volume = "39",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "18",
}